Hangzhou Just Biotherapeutics develops antibody and recombinant protein biotherapeutics. Led by Co-founder and CEO Dr. Yining Zhao, the company leverages protein, process and manufacturing sciences and is affiliated with Just Biotherapeutics, Inc. through a joint venture. As an affiliate it will have access to Just’s integrated J.DESIGN technology platform to apply to molecule, process, product, manufacturing and plant design. Applying J.DESIGN aims to accelerate biologics development and substantially reduce manufacturing cost. The company has established clinical development and CMC capabilities and maintains a pipeline of both bionovel and biosimilar products, with several programs slated to enter the clinical stage in 2018. It intends to use the Series B proceeds to further advance biologics development and clinical trials and was founded in February 2016 in Hangzhou as a joint venture with Just Biotherapeutics, Inc. Just Biotherapeutics is focused on expanding global access to important protein therapeutics through integrated design of better therapeutic molecules and more efficient manufacturing plants. The company aims to overcome scientific and technical hurdles that increase cost and restrict access to life-changing protein therapeutics. Just plans to complete new lab space, a pilot plant and GMP manufacturing capabilities to accelerate development of lower-cost biologics. Leadership includes CEO and co-founder Jim Thomas and an experienced team in protein, process and manufacturing sciences. Financially, Just closed a $14M Series A2, previously raised an initial $15M Series A, and has been awarded grant funding from the Bill & Melinda Gates Foundation of up to $24M over four years to support development of lower-cost monoclonal antibodies and sequence-optimized broadly neutralizing anti-HIV antibodies. The company was founded in 2014 and is based in Seattle. Just Biotherapeutics develops technologies to expand global access to complex protein therapeutics, focusing on both molecule design and manufacturing efficiency. The company secured $15M in Series A financing to support design of technologies that accelerate development and lower manufacturing costs. It is led by CEO Jim Thomas and a team experienced in protein, process and manufacturing sciences. Just plans to apply its manufacturing innovations toward production and commercialization of new products in developed markets and through collaborations. The company is also exploring opportunities to use its technologies to broaden product access starting with China. In addition to the equity investment, Just has an agreement with Merck to develop cost-lowering biologics manufacturing technologies.

Total raised

$86M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2017